On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0% of baseline body weight at 16 weeks and 5.2% at 24 weeks

EX-10.9 9 a25623orexv10w9.htm EXHIBIT 10.9 exv10w9
 

EXHIBIT 10.9
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
December 6, 2006
Jennifer Hooper McCarty, PhD
Technology and Research Collaborations
Oregon Health & Science University
2525 SW 1st Avenue, Suite 120
Mail Code: AD120
Portland, OR ###-###-####
Re:   Correction of Provisional Application Number/License Agreement with Orexigen Therapeutics, Inc. dated June 23, 2003 (the “License Agreement”)
Dear Jennifer:
As we have discussed in our recent email exchanges, Section 1.01.3 of the above-referenced License Agreement contains an incorrect reference to the Therapeutic Patent that is the subject of the License Agreement. Section 1.01.3 should read in its entirety as follows:
1.01.3 [***] (hereinafter: Therapeutic Patent)
Please indicate your agreement that the above reference is correct by signing where provided below. By executing this letter, we both agree that the License Agreement shall be amended by amending and restating Section 1.01.3 as provided above.
Thank you for your continued support of Orexigen Therapeutics.
Very truly yours,
     
 
  Digitally signed by
 
  Anthony McKinney
/s/ Anthony McKinney
  Date: 2006.12.06
Anthony A. McKinney
    17:10:17 - -08'00'
Chief Operating Officer
Approved and accepted the 11th day of December, 2006:
Oregon Health & Science University
       
   
By:   /s/ Arundeep S. Pradhan    
Name:   Arundeep S. Pradhan   
Title:   Director, Technology & Research Collaborations  
 
Orexigen Therapeutics Inc.
12481 High Bluff Drive, Suite 160, San Diego CA 92130
Office: 858 ###-###-####
Fax: 858 ###-###-####
www.orexigen.com
 
***   Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.